Tracking new bladder cancer treatment in everyday practice
NCT ID NCT07309445
Summary
This study follows 150 people with early-stage bladder cancer who have already started treatment with TAR-200 in real-world settings after its FDA approval. The goal is to see how long the treatment keeps the cancer from coming back or getting worse in everyday medical practice, outside of a controlled clinical trial. Researchers will track outcomes like cancer recurrence, survival, and side effects to understand how the treatment performs for typical patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-MUSCLE INVASIVE BLADDER NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Arkansas Urology
RECRUITINGLittle Rock, Arkansas, 72211, United States
Conditions
Explore the condition pages connected to this study.